Back to top

cell-therapy: Archive

Zacks Equity Research

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.

IOVANegative Net Change MRKNegative Net Change TGTXNegative Net Change AMRXNegative Net Change